FOSTER CITY, Calif.– MedGenome, a global leader in multiomics and precision medicine, today announced the appointment of two distinguished executives to lead its U.S. operations. Felix Olale, M.D., Ph.D., has been named President and Chief Executive Officer, and Jennifer Rose joins as Executive Vice President and Chief Commercial Officer. Together, these seasoned industry veterans will fuel MedGenome’s expansion in North America, advancing its mission to provide unparalleled insights into disease mechanisms, biomarkers, and personalized medicine through cutting-edge multiomics solutions.
Dr. Olale, a global leader in genomics and healthcare, most recently served as Global Co-Lead of Healthcare Investments at LeapFrog Investments, a pioneer in impact investing and a global expert in scaling purpose-driven businesses. His leadership at MedGenome will accelerate the company’s transformation into the preferred partner for academic institutions, biopharma, and biotech companies seeking advanced multiomic and genomic technologies to tackle the most challenging scientific questions, helping them develop medicines for patients in areas of unmet need.
“MedGenome is at the forefront of innovation, partnering with researchers and biopharma companies who seek more than just multiomics services—they are looking for a true collaborator to unlock deeper insights into the biology of disease,” said Dr. Felix Olale, President and CEO of MedGenome U.S. “Jennifer and I are excited to lead this next phase of growth, leveraging our comprehensive multiomic platform to drive breakthroughs in personalized medicine, drug discovery, and genetic disease treatment. Our goal is to combine these advanced technologies with AI and machine learning to deliver precision medicine solutions that will reshape healthcare.”
MedGenome U.S., headquartered in Foster City, Calif., in the heart of Silicon Valley, offers a robust portfolio of multiomic services that integrate genomics, epigenomics, transcriptomics, and proteomics. MedGenome’s team of world-class scientists and bioinformaticians work closely with customers to solve the most complex challenges in rare diseases, oncology, and genetic disorders.
“We are at a pivotal moment in genomics as it becomes a powerful engine for precision medicine,” said Jennifer Rose, MedGenome’s Chief Commercial Officer. “MedGenome’s unparalleled global reach, especially in India, South Asia, Africa, and Latin America, combined with our advanced capabilities in spatial transcriptomics, single-cell sequencing, long-read technologies and genomics-driven antibody drug discovery, uniquely positions us to deliver cutting-edge solutions for drug discovery, novel diagnostics, and personalized therapies. We are committed to partnering with biopharma to harness these transformative technologies, revolutionizing patient care and improving outcomes for millions worldwide.”
Dr. Olale’s appointment as CEO follows his previous role as Chairman of MedGenome’s Board of Directors, where he played a pivotal role in shaping the company’s strategy. He steps into his leadership role as Dr. Amit Kakar, Managing Partner and Head of Novo Holdings Asia, takes over as Chairman.
“With Felix leading our North American operations and Dr. Vedam Ramprasad driving our business in India, we have the leadership team in place to accelerate MedGenome’s growth and dramatically expand its global impact,” said Mahesh Pratapneni, CEO of MedGenome.
Jennifer Rose brings extensive expertise in life sciences, having previously served as Regional Vice President of Business Development at Precision for Medicine, a global clinical research organization. She has held senior leadership roles at NeoGenomics Laboratories, GE Healthcare, PerkinElmer, and Thomson Reuters. Jennifer holds a Master’s degree in Chemical Engineering from the University of Connecticut and a Bachelor’s degree from Clemson University.
With this new leadership team, MedGenome U.S. is primed to deepen its partnerships with biopharma and academic researchers, expand its market footprint, and deliver the next generation of multiomic technologies along with end-to-end drug discovery support, positioning it to transform the future of personalized medicine.
